JH 06
Alternative Names: JH-06Latest Information Update: 12 Dec 2023
At a glance
- Originator Bivision Pharmaceuticals
- Class Antineoplastics; Drug conjugates; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Dec 2023 Preclinical trials in Solid tumours (Diagnosis) in China (unspecified route) before December 2023 (Bivision Pharmaceuticals pipeline; December 2023)
- 12 Dec 2023 Preclinical trials in Solid tumours in China (unspecified route) before December 2023 (Bivision Pharmaceuticals pipeline; December 2023)